Stereotactic body radiation therapy in lymph nodal oligometastatic disease

Phase 2

Recruiting

• Conditions: Health Condition 1: C00-D49- Neoplasms

• Registration Number: CTRI/2023/02/049773
• Lead Sponsor: PGIMER CHANDIGARH

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 29 April 2024

Recruitment & Eligibility

• Status: Open to Recruitment
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

Lymph node oligometastatic disease in the neck, mediastinum, retroperitoneum, or pelvis

2) All primary tumors of colorectal, gastric, esophagus, lung, breast, gynaecological cancers or any other site

3) KPS = 70

4) Age > 18 years

Exclusion Criteria

More than 5 metastases

2) KPS = 60

3) Pre-existing collagen vascular disease

4) Age < 18 years

5) Pregnant and Lactating women

6) Disseminated disease

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
1) To assess Overall survival <br/ ><br>2) To assess Progression Free Survival <br/ ><br>Timepoint: 6 months, 1 year <br/ ><br>

Secondary Outcome Measures

Name	Time	Method
1)To evaluate adverse events according CTCAE <br/ ><br>2)To evaluate chemotherapy-free survival <br/ ><br>3)Quality of life with EORTC QLC C30 <br/ ><br>Timepoint: At 3 months, 6 months, 12 months